Medicaid Coverage and Utilization for Novel Therapies for Chronic Rhinosinusitis With Nasal Polyposis
Most state Medicaid programs granted omalizumab (91.4%) and dupilumab (59.5%) preferred drug status. Omalizumab was the most commonly prescribed therapy among Medicaid patients between 2015 and2024.
Authors
- George A. Scangas (ORCID: https://orcid.org/0000-0002-6687-788X)
- R. Schlosser
- Sriram Satyavolu
- Yufan Lin (ORCID: https://orcid.org/0000-0003-4087-7977)
- Zachary M. Soler (ORCID: https://orcid.org/0000-0002-4304-595X)
- Ashley L. Miller (ORCID: https://orcid.org/0000-0002-7111-4393)
- Vinay K. Rathi
- Eric R. Ramos
Institutions
- Massachusetts Eye and Ear Infirmary (US)
- Nationwide Children's Hospital (US)
- Medical University of South Carolina (US)
- Ralph H. Johnson VA Medical Center (US)
- Center for Innovation (US)
- The Ohio State University (US)
Publication Details
- Journal
- International Forum of Allergy & Rhinology
- Published
- 2026-01-22
- DOI
- https://doi.org/10.1002/alr.70109
- Citations
- 1
- Primary Topic
- Sinusitis and nasal conditions
- Type
- article
- Field-Weighted Citation Impact
- 53.14